logo
Twitter
Discord
Email
logo
Danaher Corporation

Danaher Corporation

NYSE•DHR
CEO: Mr. Steven M. Rales
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1978-12-29
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Contact Information
2200 Pennsylvania Avenue, North West, Suite 800 West, Washington, DC, 20037-1701, United States
202-828-0850
www.danaher.com
Market Cap
$155.41B
P/E (TTM)
44.0
vs Industry 33.7
Dividend Yield (TTM)
0.6%
52W High
$258.23
52W Low
$171.00
52W Range
53%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2025 Data

Revenue

$5.94B+3.36%
4-Quarter Trend

EPS

$0.77-37.40%
4-Quarter Trend

FCF

$1.09B-3.54%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

McKesson CorporationMCK
$377.60B
+20.3%
Pfizer Inc.PFE
$63.83B
+13.5%
SanofiSNY
$46.90B
+9.3%

Gross Margin (Latest Quarter)

Gilead Sciences, Inc.GILD
78.8%
+1.0 pp
SanofiSNY
72.1%
-19.0 pp
Boston Scientific CorporationBSX
67.7%
+4.9 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TMO$210.57B32.113.3%34.8%
ISRG$194.83B70.815.6%0.0%
AMGN$157.25B23.797.9%63.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+0.8%
Moderate Growth
4-Quarter Net Income CAGR
-12.1%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow Performance

Research & Insights

Reports
All Years
  • Form 10-Q - Q2 2025

    Period End: Jun 27, 2025|Filed: Jul 22, 2025|
    Revenue: $5.94B+3.4%
    |
    EPS: $0.77-37.4%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 28, 2025|Filed: Apr 22, 2025|
    Revenue: $5.74B-0.9%
    |
    EPS: $1.33-9.5%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 20, 2025|
    Revenue: $23.88B-0.1%
    |
    EPS: $5.33-17.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 27, 2024|Filed: Oct 22, 2024|
    Revenue: $5.80B+3.1%
    |
    EPS: $1.13-26.1%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 28, 2024|Filed: Jul 23, 2024|
    Revenue: $5.74B-19.8%
    |
    EPS: $1.23-18.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 29, 2024|Filed: Apr 23, 2024|
    Revenue: $5.80B-2.6%
    |
    EPS: $1.47-25.0%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $23.89B-10.3%
    |
    EPS: $6.44-34.3%
    Beat
  • Form 10-Q - Q3 2023

    Period End: Sep 29, 2023|Filed: Oct 24, 2023|
    Revenue: $5.62B-26.6%
    |
    EPS: $1.53-28.2%
    Miss